A counterparty your teams can examine.
Drovix brings institutional liquidity, its own market-making and bridge technology to the execution relationship. Give your desk, risk and operations teams a clear view of the responsibilities around it.
Responsibility matrix
One execution arrangement.
Three internal perspectives.
Select a review team. The matrix connects its questions to the instruction lifecycle; the notes below connect them to Drovix.
Scroll the table to compare teams, or use “Read selected detail” to go directly to your chosen team’s notes.
| Review point | Dealing desk | Risk & legal | Operations |
|---|---|---|---|
| Before dealing | Instrument scope and dealing authority | Entity, eligibility and agreement | Identifiers, formats and reporting scope |
| At the instruction | Trading intent and permitted action | Approved exposure and risk boundaries | Order-state interpretation and records |
| After execution | Outcome against the programme | Exceptions and ongoing counterparty review | Reconciliation and investigation ownership |
Dealing desk / Review lens
The instruction has to fit the mandate.
The desk owns the trading intent and authorised instructions. Review how Drovix’s liquidity, pricing and execution scope fit the programme—and how your desk will interpret the returned records.
Execution policyDrovix’s side of the arrangement
Liquidity.
Market-making.
Bridge technology.
Drovix combines the institutional counterparty role with its own pricing and connectivity technology. Your institution’s mandate, internal authorisations and approval decisions remain yours. The agreement defines the boundary between the two.
Continue the review
Committee review references
These public references explain the framework. Confirm the terms and technical scope applicable to your arrangement with the desk.
Talk to the institutional desk
Bring your institution’s requirements into view.
Discuss the execution programme, contractual scope and operating responsibilities with the institutional desk.
Contact DrovixLeveraged OTC products, including Forex and CFDs, carry a high level of risk and a counterparty may lose more than its initial margin. The Drovix offering is directed exclusively at Eligible Counterparties and Professional Clients; Drovix does not provide services to retail clients. Content on this page is factual and descriptive only and does not constitute investment advice, a recommendation, or an offer or solicitation to transact.
Drovix acts as principal in bilateral OTC transactions with approved institutional counterparties. It is not a public exchange, MTF, OTF or ECN. Services are not offered to retail clients or in jurisdictions where Drovix is not authorised or permitted to provide them. Instrument access, connectivity, risk parameters and commercial terms are subject to review and the signed institutional services agreement.